The Rise Of Marketing-Based Medicine (via Pharmalot)

The Rise Of Marketing-Based Medicine


By Ed Silverman // January 28th, 2010 // 7:57 am

money13You've heard of evidence-based medicine. Well, a new paper summarizes a panoply of practices employed over the past two decades or so - ghostwriting, suppressing or spinning data, disease mongering and managing side effect perceptions among docs - that the authors call marketing-based medicine. And they rely on internal documents from litigation - such as the much-publicized lawsuits over antipsychotics and antidepressants - to illustrate their point.

A stunning must-read from Ed Silverman on a must-read paper. The comments following Ed's post are also rich.

I imagine there will be blowback and some vigorous challenges to the facts and stats in the paper. But the industry emails quoted are themselves devastating, and suggest how successfully the marketing forces within the industry won out over those who wanted to make drugs that clearly worked, rather than aggressively sell drugs that either didn't work that well or worked for some but carried nasty side-effects that were downplayed.

Pharma, biotech, and medicine itself will be years digging out of the credibility hole this sort of thing put them in.

Posted via web from David Dobbs's Somatic Marker

More like this

I'm having difficulty even reading, much less posting about, the river of stories about pharma and device industries, FDA regs, conflicts of interest, and so on. But I'll take a stab here at spotlighting the main events and making some sense of where this is headed. For I don't think it's just…
Neuroskeptic ponders the growing evidence that antidepressants significantly best placebo only in the more (or most) depressed patients. His take is that: antidepressants treat classical clinical depression, of the kind that psychiatrists in 1960 would have recognized. This is the kind of…
What's wrong -- but horribly expected -- in this picture? One week the CEO of Lilly attacks the idea of a public health insurance plan because it might reduce consumers' "ability to choose, in an informed way, from all the available alternatives." The next week, PhRMA, the trade group this CEO's…
Here and elsewhere in the blogosphere, over the last several years, what started out as a more general interest in skepticism and science with a natural focus on medicine and a side interest in combatting Holocaust denial became more focused on promoting science-based medicine. As the saying goes…

My favorite side effect from the drug commercials (I forget which drug, unfortunately) is "skeletal pain."
Ow. My skeleton hurts.
If you can't develop new treatments for old diseases, just invent new diseases for your old treatments.